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ABSTRACT 
This thesis investigated the impact of manufacturing process modifications for the 
bulk manufacture of curcumin implants for diabetic neuropathy pain relief. A homogeneous 
mixture of poly(caprolactone) (PCL) and curcumin was blended using cryomilling as an 
alternative to the solvent mixing method. Cryomilling was selected due to its faster 
processing time and reduced cost of materials in comparison to the solvent method. X-ray 
diffraction (XRD) was used to characterize the resulting mixture to determine the efficacy of 
cryomilling as an option for blending curcumin and PCL powders. In addition to cryomilling, 
compression molding was selected as the manufacturing method to allow for the creation of 
implant molds featuring threaded geometry on the millirod surface. Implants were 
subsequently evaluated in vitro for 30 days. Curcumin loaded millirod implants with 
complex threaded surface geometry were found to have a higher, but not significant, percent 
mass loss after degradation and average daily curcumin release than the cylindrical implants.  
It can be concluded that the utilization of cryomilling for the creation of curcumin loaded 
implants in bulk is an easier to manipulate and more cost effective method of combining PCL 
and curcumin without sacrificing implant effectiveness. 
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CHAPTER I: GENERAL INTRODUCTION 
Diabetic neuropathy stems from nerve damage caused by elevated blood sugar levels 
for a prolonged period of time. Neuropathy in diabetics usually manifests in the legs and feet 
and the resulting pain is difficult to manage [1-4]. Current accepted anti-inflammatory agents 
to manage neuropathy pain, such as tricyclic antidepressants, pregabalin, or duloxetine, carry 
negative side effects including dizziness, weight gain, or arrhythmias [1]. There is a need for 
an active treatment to help with the management of pain caused by neuropathy that gives 
patients better pain relief without the negative side effects.   
Curcumin is a natural polyphenolic found in turmeric (Curcuma longa) that has been 
shown to disrupt inflammatory pathways in cells [5-7]. Additional studies have linked 
curcumin to modulation of curcumin to anti-oxidant factors [8]. The ability for modulation of 
these pathways is increasingly important as diabetes and inflammation are linked [9, 10]. 
The major challenge facing curcumin as a viable anti-inflammatory agent is its low 
bioavailability due to poor absorption and rapid metabolism of the compound when ingested 
[11]. Therefore it is necessary to encapsulate curcumin in order to ensure that the compound 
maintains its effectiveness as an anti-inflammatory agent. Encapsulation would protect the 
compound from premature release into the body and allows for continued release over the 
life of the implant. To increase the drug effectiveness, curcumin should not be introduced to 
the body orally, but rather implanted locally to the site of discomfort or intraperitoneally [12-
14].  
Previous work has successfully created cylindrical curcumin implants [14], but little 
work has been done on the effect of different geometries on drug release rate. Other studies 
have linked an increased surface area to higher implant degradation and drug release rates 
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[15]. Bansal et al. did an in vivo evaluation of curcumin loaded polymer implants in 
subcutaneous tissue in rats to confirm its effectiveness as a chemopreventive delivery system 
[16]. By modifying the shape of the implant to increase surface area, the release rate of the 
dose can be customized. The proposed implant geometry for this research is a cylinder with a 
threaded surface feature, allowing for additional surface area while maintaining ease of 
manufacture.  
The rationale for using a threaded implant geometry is that the implant shape 
increases surface area while providing texture for the implant to anchor to the fascia 
connective tissues in the body to reduce implant mobility after insertion. Fabrication of this 
implant was done via compression molding using poly(caprolactone) acid (PCL) 
incorporated with curcumin. 
Curcumin was encapsulated with molded PCL to achieve controlled sustained release 
at the implant site. PCL is a Federal Drug Administration (FDA) approved polymer for 
human clinical use due to its proven biocompatibility and low toxicity. This product does not 
accumulate in vital organs and is created in the process of carbohydrate metabolism. 
Controlling the surface area of the implant will regulate drug release. 
One combination ratio of curcumin and PCL was fabricated: 15% curcumin-85% 
PCL, in two different geometry types: threaded or cylindrical. The drug load percentage was 
selected from the previously tested loading range of 2-50%, of which drug loads greater than 
10% had constant drug release [14]. In order to have the curcumin suspended in the PCL, 
samples were cryomilled to reduce particle size and blend the two components. The resulting 
polymer-curcumin mixture underwent compression molding at 71 °C. Samples were then 
extracted from the mold and processed to remove any flash or residual material.  
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Implants were then placed in amber vials in a solution of 10 mLs phosphate buffer 
solution (pH 7.4) and supplemented with 10% v/v bovine calf serum to simulate the body 
environment. Vials were incubated at 37° C on a shaker table at 150 rpm. Implant media was 
changed every 48 hours and the implants were weighed to determine total percent mass loss. 
Degradation media was analyzed via spectrophotometer to confirm average curcumin release 
per day of degradation. 
 XRD analysis of the cryomilled curcumin polymer mix retained a key characteristic 
peak of curcumin near the 10° mark. This peak was not present in the solvent mixed 
curcumin and PCL indicating that cryomilling does not mask the major characteristic peak of 
curcumin to the extent that solvent mixing does. The results from the degradation showed 
that the degradation of the threaded geometry implant had a significant increase in the 
percent mass loss and the average daily release of curcumin over cylindrical curcumin loaded 
implants.  
 
Thesis Organization 
 The format of this thesis is as follows. Chapter 2 is a literature review encompassing 
previous research involving curcumin as an anti-inflammatory agent, curcumin based 
implants, and evaluation of created implants. Chapter 3 covers previous research related to 
drug delivery systems that led to this project. Chapter 4 contains the manuscript to be 
submitted to the Journal of Manufacturing Processes and covers the main experiment of this 
thesis outlining the effect of geometry shape on in vitro degradation behavior of curcumin 
implants. A general conclusion can be found in Chapter 4 in addition to future work.   
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CHAPTER II: LITERATURE REVIEW 
2. 1 Painful Diabetic Neuropathy 
According to the American Diabetes Association, 30 million Americans have 
diabetes and 60-70% of diabetics suffer from diabetic neuropathy [17]. Painful diabetic 
neuropathy (PDN) is associated with numbness in the legs and feet, but can be described as a 
stabbing or burning sensation in severe cases. Although the pain from PDN is not life 
threatening, it does impact a diabetic’s quality of life as numbness can lead to an increased 
risk of falling, ulcers or amputation [18, 19].  
Neuropathy in diabetics is caused by the increased demand of nerve endings in the 
body due to elevated glucose levels in the blood for an extended period of time. The excess 
glucose in the cell system results in additional glycolysis that can overload the electron 
transport chain resulting in the creation of reactive oxygen species (ROS) [20]. Increased flux 
through different signaling pathways also result in oxidative stress and inflammatory injury 
[20, 21]. 
  
2.2 Synthetic Drugs Used for Painful Diabetic Neuropathy 
 Complete relief for diabetic neuropathy pain is difficult to achieve, as there are no 
treatments currently on the market that relieve associated pain completely. Since PDN is 
highly correlated to hyperglycemia, strategies to control a patient’s glycemic index are 
generally considered the first step in PDN management [1, 22, 23].  However, certain kinds 
of antidepressants and antiepileptic drugs have had some effect on reducing pain perception 
in patients. 
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Tricyclic antidepressants like amitriptyline work by preventing reuptake of 
noradrenaline and serotonin in the brain, allowing these neurotransmitters to collect and 
effectively block pain signals along the spinal cord [24]. Like most antidepressants, 
determining actual dosage requires trial and error and patients may not see any changes in 
pain for several weeks after starting the medication. Amitriptyline is not without its side 
effects which can include dizziness, dry mouth, and weight gain [25-27]. More serious side 
effects can include seizures, hallucinations, or hypersensitivity syndrome [28, 29].  
Antiepileptic drugs are also currently being used to manage neuropathy pain. Some 
commonly prescribed antiepileptics for PDN include gabapentin and pregabalin. Gabapentin 
is well tolerated medication with minor side effects such as drowsiness. However a crossover 
study comparing gabapentin and amitriptyline for PDN pain relief found amitriptyline to 
provide greater pain relief [30]. Pregabalin is another commonly prescribed medication for 
the treatment of PDN, and while it is mostly well tolerated, it has rare side effects that 
include acute renal failure and acute angle glaucoma [1]. 
As previously mentioned, pain relief for diabetic neuropathy is difficult to manage, 
even with the introduction of an antidepressant or antiepileptic drug. In many of the studies 
looking at the efficacy of these drugs for mitigating PDN pain, a drug therapy is considered 
successful with a 50% reduction in pain [1]. Current offerings leave patients with PDN 
having to trade off potentially serious side effects for incomplete pain management.  
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2.3 Non-Pharmaceutical Alternatives 
2.3.1 Capsaicin 
Several studies have analyzed the efficacy of topical capsaicin creams to help treat 
PDN symptoms. Capsaicin is responsible for the pungent trigeminal sense of heat during 
consumption of peppers. Repeated application of capsaicin to skin has been shown to 
inactivate nociceptors resulting in decreased sensitivity to heat and mechanical stimuli [31]. 
However, application of creams must be done using gloves to reduce the risk of cross 
contamination of capsaicin to other parts of the body, such as the face. Introduction of 
capsaicin to open wounds is not recommended and patients may experience localized burning 
or stinging at the application site during the first week of treatment [1]. A review of capsaicin 
efficacy found moderate improvements in treatment of neuropathic pain, but stated that 
capsaicin creams may be better as an adjunct therapy or sole therapy for patients who are 
intolerant of other types of pain management [32]. 
 
2.3.2 Traditional Chinese Medicine 
 Traditional Chinese medicine (TCM) is an ancient form of healthcare in China that 
utilizes herbal medicines in addition to acupuncture and massage [33]. Over 80 herbal 
medicines have been characterized with antidiabetic effects, 10 of which are frequently used 
for diabetes and related complications [34, 35]. The main compound prescribed for diabetes 
is Radix astragali, which is derived from Astragalus membranceus [36]. The active 
polysaccharides in R. astragali are thought to modulate hypoglycemia in patients in addition 
to having an anti-inflammatory effect by disrupting several different inflammatory pathways 
[9]. Ginseng (Radix ginseng) is another common TCM that is used for management of 
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hyperglycemia through increased production and sensitivity to insulin [37]. However the 
largest challenge facing the herbal component of TCM is acceptance and quantification of 
the effects of herbal remedies. Future use of these homeopathic remedies depends heavily on 
the validation and analysis of active compounds in TCM through modern evaluation 
techniques and controlled studies.  
 
2.3.3 Curcumin 
Curcumin is a minor component found in the spice turmeric. Curcuminoids, 
consisting primarily of curcumin and cyclic curcumin, make up roughly 2%-9% of turmeric 
and can be extracted in a variety of means [38]. As a drug, curcumin has been shown to be an 
effective anti-inflammatory agent in previous studies for a variety of diseases including 
cancer and cardiovascular disease [39-41]. Curcumin has also shown anti hyperglycemic 
effects in previous studies with type 2 diabetics [42]. As mentioned earlier, control of a 
patient’s glycemic index is a key component to managing PDN. 
However, curcumin is rapidly metabolized into glucuronides and curcumin sulfates 
by the body when orally ingested, requiring large initial doses to be ingested for therapeutic 
effects to be seen [43]. Cheng et al. reported no dose limiting toxicity at 8,000 mg/day of 
curcumin, and similar studies confirm no toxicity at dosages as high as 12,000 mg/day [44, 
45].   Analysis of serum concentrations in humans taking 8,000 mg doses showed a peak 
concentration of 3.6 μM of curcumin one hour after oral intake which then held steady at 0.6 
μM for the next 20 hours [44]. This facilitates the need to encapsulate curcumin to ensure 
that the active compounds remain effective systemically. Attachment of curcumin to other 
components like liposomes, polymers and surfactants have been shown to reduce the 
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degradation of curcumin [46]. An implantation device loaded with curcumin and placed 
subcutaneously or intraperitoneally in the body would bypass the digestive system and liver 
and allow for higher curcumin levels in plasma [47].  
 
2.5 Cryomilling  
 In order to create an effective polymer-drug matrix, previous curcumin implant 
studies have utilized solvent evaporation to encapsulate the hydrophobic spice [14, 48-50]. 
This method requires that the curcumin be dissolved in dichloromethane (DCM) while the 
polymer be dissolved in ethanol. These two solutions would then be mixed together and their 
solvents would be evaporated off overnight [14].  
In order to more rapidly create a polymer-drug matrix, cryomilling can be used to 
reduce the processing time to under an hour, depending on the parameters set. Cryomilling 
subjects samples to low temperatures through the use of liquid nitrogen. At this low 
temperature, materials are beyond their crystalline point making them very brittle. 
Cryomilling utilizes this key material property change to mix and refine the particle size. One 
of the large advantages to utilizing cryomilling is that no solvents are required for mixing, 
especially since both ethanol and DCM can be hazardous when handled [51, 52]. Using a 
solvent also runs the risk of having residual solvent remain in the PCL and curcumin mixture. 
Gupta et al. evaluated the residual levels of DCM in solvent mixed PCL and curcumin via 
GC-MS and found no DCM at a detection level of <1.6 ppm [15]. Estimates of the cost of 
liquid nitrogen have been previously stated as $1/L [53]. However, the cost of liquid nitrogen 
to operate the cryomill from the Iowa State Chemistry Stores is $0.85/L. In comparison, 200 
proof ethanol and dicholormethane currently go for $100/L and $58/L respectively when 
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purchased through Sigma Aldrich (does not include cost of shipping).  Using the small 
benchtop cryomill [SPEX Sample Prep Freezer Mill 6770 (Metuchen, NJ, USA)] 2L of 
liquid nitrogen can process 5.70 g of PCL and curcumin mixture. This is enough to fabricate 
72 threaded geometry implants for a cost of $0.023 per implant.  To solvent mix the same 
mass of PCL and curcumin, about 12.60 mL of dicholormethane and 6 mL of ethanol are 
required to dissolve the individual implant components prior to combination. This would 
produce 72 threaded geometry implants at a cost of $0.023 per implant but does not include 
additional waiting costs incurred for solvent evaporation. 
Previous work has looked at the efficacy of creating large quantities of curcumin and 
polymer blends via cryomilling [54]. Based on their findings, Wegiel et al. determined 
cryomilling was an effective method of creating amorphous curcumin and polymer powders 
in large quantities. However, no mixing of PCL and curcumin was done in this study.  
 
2.6 Drug Delivery Implants 
 
Figure 2.1: Types of implantable drug delivery systems, their implantation devices, and 
example in vivo implantation locations [55]. 
 
 
Wolinsky (2012) 
10 
 
 
 
2.6.1 Implants 
 The previously mentioned pharmaceutical solutions for PDN pain management are 
administered in a form that is taken orally. This route normally results in the metabolism of 
the drug in the liver and is transported through the body via the bloodstream.  However, a 
growing trend in drug delivery systems research is the investigation of drug loaded 
implantable or injectable self-assembling devices as a method to deliver more effective doses 
to the area of need. After implantation, the device degrades, simultaneously releasing the 
loaded drug into the immediate area. An implant specifically designed for diabetic 
neuropathy pain relief would ideally be designed to be minimally invasive, easy to insert into 
the target area, and provide effective relief for an extended period of time. There are several 
different types of implants currently being researched for drug delivery applications that 
could be used for PDN management including hydrogels, films, wafers and millirods. Some 
of the drug delivery options, implant locations, and implant devices can be found in Figure 
2.1. 
 
2.6.2 Hydrogels 
Hydrogels are composed of hydrophilic polymer chains that can absorb large amounts 
of water and can be made in stable or degradable forms [56]. There is no set chemical 
formulation that characterizes a hydrogel, as many different material combinations can be 
utilized to obtain a hydrogel with the desired liquid loading characteristics [57-59].These gels 
are easily mixed with small molecule hydrophilic drugs, and inclusion of hydrophobic 
domains within a hydrogel can help with the dispersion of hydrophobic drugs [60].  
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Applications for hydrogels in drug delivery include cancer and treatment of 
inflammatory bowel disease (IBD). Localized delivery of chemotherapeutics would minimize 
damage to healthy cells as some anti-cancer drugs cannot distinguish between cancer cells 
and normal cell tissue [61].  Guo et al. created a linoleic acid conjugated poloxamer hydrogel 
for the application of long term delivery of anti-cancer drugs resulting in the disruption of 
Akt 1 signals [62]. Similarly, chitosan hydrogels loaded with a variety of anti-cancer drugs 
including paclitaxel and camptothecin have been evaluated as alternative delivery 
mechanisms in different cancer types with some success in vitro and in vivo [63, 64].  In 
another application, a negatively charged ascorbyl palmate hydrogel was created for the 
delivery of anti-inflammatory drugs for IBD treatment [65]. Evaluation of the hydrogel in 
mice found a decreased severity of the disease in mice treated with the drug loaded hydrogel. 
Utilization of the hydrogel also limited the spread of the anti-inflammatory drugs to other 
parts of the body, as the serum concentration for the hydrogel group was lower than that of 
the control group using the free form of the drug.  
  One of the challenges facing hydrogels is during the implantation phase. 
Thermosensitive hydrogels remain in an aqueous form at room temperature for easy injection 
into a target site. Once at body temperature it assembles into a gel [63]. However this 
solution still runs the risk of clogging the needle or premature gelation in the syringe itself 
[60]. 
 
2.6.3 Polymeric Films 
 Polymeric films are another method of drug delivery implants that have been 
explored for inclusion into soft tissues [55]. A common method for film creation is casting 
which involves the introduction of the liquid polymer to a mold and allowing it to cure. 
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Depending on the mold, additional processing to alter the size and shape may be needed [66]. 
Materials like silk, PLGA, PVA, and PCL have previously been successfully cast into films 
for drug delivery purposes [67-70].  
Electrospinning is another method of manufacturing polymer films through the 
creation of fibers by applying a voltage to a needle and grounding the system to a collecting 
plate [71]. The charge difference across the system helps to draw the polymer fibers from the 
polymer when it is deformed into a Taylor cone [72]. Electrospun mats can be created using 
a variety of polymers including silk, PLA, and PCL [73-75]. The thread diameter and mat 
thickness can be controlled through several parameters including time, needle gauge, 
pumping rate, voltage, and distance between the needle and the collecting plate [76]. 
Applications for electrospun mats center on active wound healing and infection prevention 
through the incorporation of drugs [77]. Uses for mats as wound dressings could include 
application external to the body to assist in burn healing, or internally to the body as a way to 
assist healing following surgery [78]. In a PDN relief application the mat would need to be 
implanted to achieve the desired prolonged degradation characteristics. 
 
2.6.4 Wafers 
 The Gliadel Wafer is the only FDA approved current market solution for patients 
requiring brain cancer treatment [79]. The Gliadel Wafer has been used in over 20,000 
procedures in the US since its launch in 1997 [80]. The wafer is deposited in a cavity of the 
brain following removal of the primary tumor [55]. Because implants are placed intra-
cranially, the effective chemotherapeutic can directly target cancerous cells in the immediate 
surroundings without the challenges of navigating the blood-brain barrier as with systemic 
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chemotherapy options. A recent study by Boateng et al. created freeze dried wafers as drug 
delivery devices for wound healing applications [81].  However, due to their physical 
characteristics, wafers are not able to be implanted via injection and must be placed 
surgically in the body, or through open wounds [55]. 
 
2.6.5 Millirods 
 Millirods are thin, preformed polymeric cylinders that can serve as extended drug 
release devices. This type of drug release solution is currently being used in the market for 
long term contraception. Progestin millirods are injected sub-dermally and can provide three 
years of contraception protection [82]. Current research is exploring millirod implants as a 
potential chemopreventive solution. In addition to an easy implantation method, millirods 
can be made using several different types of manufacturing methods including casting and 
melt extrusion [55]. At small scales, sacrificial encapsulation of the polymer in silastic tubing 
is a method of achieving millirods through melt extrusion [14]. For larger bulk scales a 
sacrificial manufacturing method is not the most efficient or cost effective route of implant 
creation. Casting, compression molding, or continuous extrusion using a fixed die would be 
manufacturing methods utilized at a larger scale. Millirods are excellent candidates for bulk 
manufacture as the main point of customization would be at the point of implantation, 
allowing for the production of implants in bulk.  
 
2.7 Effect of Geometry on Degradation 
Degradation of polymer implants tends to happen in one of two forms: surface or bulk 
erosion [83-85]. Factors affecting the degradation and erosion of a polymer can include 
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chemical interactions between polymer and drug, pH of the environment, or by the addition 
of copolymers [83]. Understanding and modeling erosion behavior of drug delivery devices 
is complicated by the introduction of water to the polymer implant which may result in 
swelling and changes in pH [83]. Geometry has only recently gained traction as a way to 
alter functionality of a drug delivery implant [86]. Findings from a study by Burkersroda et 
al. measured the degradation of cylindrical polymer matrices and found that polymers were 
able to undergo both types of degradation profiles depending on geometry and degradation 
parameters [84].  Klose et al. evaluated PLGA films and microparticles and found that the 
geometry of the delivery devices to have a large impact on the release profiles for drugs [68].  
 The focus around geometry in drug delivery systems tends to center around the 
efficacy of vascular and endothelial carriers [87, 88]. These have typically taken the form of 
microspheres, but continued research in the kinetics and release properties of different 
geometry carriers has led to the creation of ellipsoids and disks [88].  Non-spherical delivery 
devices are thought to have an advantage as vascular delivery systems due to their high 
surface area to volume characteristics allowing for increased environment interactions and 
the potential to reach more diverse targets in the body [86]. However not much work has 
been done specifically on the impact of complex geometry on drug release rates for 
subcutaneous or intraperitoneally targeted millirod implants beyond changes in millirod 
diameter [14]. 
One of the few examples of long term implantable polymer drug delivery devices 
with complex geometries was a honeycomb structure created by Yang et al [89]. This study 
was done as a proof of concept for the microfabrication and drug release kinetics. However 
there was no in-depth discussion relating the surface area to the release rate. 
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 Bansal et al. reported that with an increase in surface area there was an increase in 
observed drug release [14].  Through the evaluation of cylindrical implants at varying 
diameters it was also determined that the increased size of an implant also sees an increase in 
the surface area of the implant resulting in increased drug diffusion into the environment 
surrounding the implant. Based on this knowledge, our study chose to compare millirod 
implants with similar cylindrical forms for easy implantation, but with drastically different 
surface areas to determine the impact on drug release. 
 
2.8 Summary of Literature 
Diabetic neuropathy is a fairly common adverse symptom stemming from sustained 
increased blood glucose levels resulting in pain in the legs and feet that can lead to 
amputation [2, 18]. Antidepressants and antiepileptic drugs are the current medications used 
to mitigate the pain of diabetic neuropathy, yet successful treatment under these therapies is 
only able to achieve a 50% reduction in patient pain [1, 26, 27]. There is a need for a natural, 
long term treatment for the reduction of painful diabetic neuropathy that utilizes a drug with 
lower risk of adverse side effects. Curcumin is one such drug that exhibits anti-inflammatory, 
antioxidant, and anti-hyperglycemic effects with no dose limiting toxicity at high dosages 
[39, 41, 44]. However encapsulation is required for curcumin to remain bioavailable in the 
body. By combining curcumin and PCL via cryomilling, the additional time and materials 
needed for solvent evaporation mixing can be forgone in an effort to streamline the process 
of manufacturing for scale up. Previous millirod work determined that an increase in surface 
area saw an increased drug release rate [14].  
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CHAPTER III: PRELIMINARY WORK 
Prior to investigating the main hypothesis of this thesis, unpublished research relating 
to drug delivery was explored. Two different types of drug delivery systems, electrospun 
mats and hydrogels, were initially pursued for applications in alternative chemotherapy 
delivery and scaffolds for stimulating cell proliferation respectively. Techniques and 
learnings from these works helped in the development of the thesis research as outlined in 
Chapter 4. 
 
3.1 Electrospinning of Silk 
The initial goal of this work was to develop a non-systemic chemotherapy drug 
delivery device for the treatment of local breast cancer recurrence. Investigation was focused 
on finding a method of drug delivery that was not utilized for chemotherapy solutions. 
Selection of materials was based on high performing polymers with low in vivo toxicity. The 
manufacture of this delivery system also needed to be repeatable and scalable for ease of 
manufacturing purposes.  
 Ultimately this project continued previous work from the iMED laboratory on the 
evaluation of electrospun polymer blends, including PCL and polyglycolide, for use as drug 
delivery systems [90, 91]. As mentioned previously in section 2.6.1, electrospinning is a 
method of creating micro or nano scale diameter polymer fibers by utilizing an electric field. 
The experimental setup can be found in Figure 3.1. By applying a high voltage to a polymer 
loaded syringe needle and grounding the collecting plate, a large charge differential is 
created. A syringe pump slowly releases polymer from the syringe tip and the voltage 
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deforms the polymer bead creating a Taylor cone. This results in the release of fine diameter 
polymer fibers that are collected on the grounded plate. These polymer mats have a high 
surface area to volume ratio which is beneficial in drug release [75]. In contrast to previous 
iMED studies silk was selected as the main polymer component for electrospinning due to its 
beneficial properties as a biomaterial. Silk fibroin extracted from Bombyx mori cocoons have 
been found to have comparable degradation rates to other synthetic polymers, but with a 
reduced inflammatory response over PLA or collagen films [92]. Silk films have been used 
in combination with chemotherapeutic drugs like doxorubicin for in vivo breast cancer 
evaluation with positive results. The films showed a decrease in tumor weight and reduced 
metastatic spread, in addition to outperforming all other tested treatments [67].  
 Attempts to create silk electrospun mats were based on previous research 
methodologies [74, 93, 94]. Extraction of silk fibroin followed the protocol set forth by 
Rockwood et al [94]. Briefly, B. mori cocoons were opened and the silkworms were removed 
before being added to boiling water and sodium bicarbonate to degum the cocoons. After 
degumming, the remaining silk fibroin was dissolved in lithium bromide and the resulting 
solution was added to a dialysis cassette. Following dialysis, the resulting fibroin solution 
was centrifuged. Parameters used for electrospinning the fibroin solution were as follows: 
Pump rate was 0.02 mL/minute, voltage was set to 15 kV, silk concentration was 8% by 
weight and was combined with a 5 mL of a 5% PEO solution dissolved in water, and distance 
from the collecting plate was 10 cm. After electrospinning, PEO was dissolved using 70% 
vol/vol ethanol and allowed to dry. Spun fibers prior to PEO removal can be seen in Figure 
3.2.  
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Despite successfully electrospinning a small amount of silk fiber on one occasion it 
was determined that long term storage of fibroin via lyophilization was needed to continue 
pursuing this material option long term due to the process intensive requirements to prepare 
the silkworm cocoons for use. Freeze drying the dissolved fibroin concentrates it, but also 
makes it stable for extended periods of time at room temperature [94]. This is in contrast to 
the silk fibroin in the solution form, which must be chilled at 4 °C and runs the risk of gelling 
rendering it useless for an electrospinning solution. 
 
Figure 3.1: General electrospinning set up [95]. 
 
Figure 3.2: SEM image of PEO/silk fibers prior to the removal of PEO. 
Ziabari (2009) 
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 The ultimate design for this drug delivery system was a two stage drug delivery 
system. The electrospun silk fiber mat loaded with either a chemotherapeutic or anti-
inflammatory drug would be spun first. A second polymer, like PLGA, loaded with a second 
drug would be spun directly on the silk mat. Testing would have determined the efficacy of 
the two different release profiles.  
 
3.2 Hydrogels for Cell Growth 
 A smaller project was done in collaboration with the Sakaguchi Lab at Iowa State 
University looking at the use of hydrogels as a medium to promote adult hippocampal stem 
cell proliferation. The main objective of the collaborative research was to have the hydrogel 
in a pipette tip used for cell culture. This was part of a larger experiment to create complex 
internal geometry in a cell proliferation scaffold to help guide the movement and growth of 
stem cells.  Table 3.1 shows the materials and quantities used for the hydrogels that were 
created. Briefly, using a calibrated pipette, each of the materials in Table 3.1 were added to a 
clean test tube in the order listed. The catalyst, TEMED, is the last to be added, and with its 
addition the ingredients react and start to foam. The foam was mixed using a scoopula for an 
additional minute and allowed to sit in a vacuum oven for 20 minutes before the addition of 
the dehydrating agent.  
Two methods of manufacture were attempted. The initial attempt tried to mix the 
hydrogel directly in the pipette tip. The small end of a 1,000 μL pipette tip was enclosed 
using Parafilm prior to introducing the chemicals to be mixed. In order to accommodate the 
smaller container size, the listed ingredient amounts were divided by five.  Despite covering 
the exit hole of the pipette tip, very little hydrogel was formed in the space due to the high 
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levels of foaming following the addition of the TEMED catalyst. This resulted in very little 
residual hydrogel left behind in the pipette tip. Future attempts made the hydrogel external to 
the pipette tip. This was done by creating the hydrogel in a test tube as previously mentioned, 
but transferring it to an aluminum foil lined petri dish prior to the vacuum drying and 
dehydration steps. This resulted in a hydrogel disk that allowed for geometry modification of 
the hydrogel prior to inserting it in the pipette tip. This method also allowed for more direct 
control on the amount of hydrogel that could be added to the pipette tip.  
Following creation, hydrogel samples were sterilized using a 70% ethanol solution 
before entering the cell culture hood and allowed to dry overnight in the UV hood prior to 
cell culture [96]. A small sample of the hydrogel was introduced to test plates containing 
Dulbecco’s Modified Eagle Medium (DMEM) and adult hippocampal stem cells were then 
added to the hydrogel via pipette. DMEM was selected to visually identify the pH changes of 
the cell medium during proliferation [97]. Evaluation of the culture after 24 hours determined 
that the hydrogel formulation was not compatible with cell culture as the environment was 
too basic for sustained cell growth due to the purple/blue color of the DMEM [98]. 
 
Table 3.1: Chemicals used to create hydrogels for the pipette tip project. 
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CHAPTER IV: BULK MANUFACTURE OF COMPLEX GEOMETRY MILLIROD 
IMPLANTS AND THEIR DEGRADATION AND DRUG DELIVERY 
CHARACTERISTICS 
 
A paper to be submitted to the proceedings for the 2016 North American Manufacturing 
Research Conference  
Melissa Slagle, Iris V. Rivero 
 
Abstract 
This study evaluated the impact of manufacturing process modifications aimed at the 
bulk manufacture of curcumin implants for diabetic neuropathy pain relief. 
Poly(caprolactone) (PCL) and curcumin were blended using cryomilling as an alternative to 
the solvent mixing method which has higher manufacturing and time delay costs. X-ray 
diffraction (XRD) was used to characterize the resulting mixture to determine the efficacy of 
cryomilling as an option for blending curcumin and PCL powders. By adopting compression 
molding as a manufacturing method we were able to create implant molds featuring threaded 
geometry on the millirod surface. Implants were subsequently evaluated in vitro for 30 days. 
Curcumin loaded millirod implants with a complex threaded surface geometry were found to 
have a higher, but not significant, percent mass loss after degradation and average daily 
curcumin release than the cylindrical implants. It can be concluded that the utilization of 
cryomilling for the creation of curcumin loaded implants in bulk is an easier to manipulate 
and more cost effective method of combining PCL and curcumin without sacrificing implant 
effectiveness. 
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4.1 Introduction 
 Type 2 diabetes is the most prevalent form of diabetes in the United States affecting 9.3% 
of the total population [1]. This form of diabetes is more commonly associated with obesity or 
lack of physical activity resulting in reduced insulin production and sensitivity [2]. In addition, 
type 2 diabetics may also suffer from additional painful or debilitating conditions as a result of 
diabetes related complications. These can include blindness, amputations, kidney problems, and 
neuropathy [1]. Of these adverse diabetic complications, 50% of diabetics experience neuropathy 
in some form, which often manifests in foot and leg pain [3, 4]. A particular form of this 
condition, painful diabetic neuropathy (PDN), remains difficult to treat, as a 50% reduction in 
pain is considered a successful treatment [5]. Current solutions for PDN treatment include the 
use of cyclic antidepressants or antiepileptic drugs, both of which have negative side effects that 
may include dizziness, blurred vision, or weight gain [5]. 
 Curcumin is a natural anti-inflammatory agent found naturally occurring in the spice 
turmeric. Many studies have been done to evaluate the impact of curcumin on various diseases 
including several different types of cancer, asthma, cardiovascular disease, and diabetes [6-13]. 
Despite the positive effects curcumin exerts as an anti-inflammatory agent, it has been shown 
that curcumin has poor bioavailability when taken orally [14]. One option to overcome this 
challenge is through encapsulation of curcumin within a polymer matrix. This type of drug 
delivery is most notably used for effective birth control through subcutaneous implantation that 
provides protection for 3 years [15]. This type of solution is ideal for treatment applications that 
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require sustained treatment over a long period of time. As PDN is a chronic disease currently 
without a cure, an implantable drug delivery device would provide an alternative method of pain 
management without jeopardizing patient quality of life.   
 Previous literature has developed cylindrical millirods impregnated with curcumin as a 
potential chemopreventive solution [7, 16-18]. Implants were manufactured using the solvent 
mixing method to create a curcumin polymer matrix. PCL was selected as the polymer as it is a 
Federal Drug Administration (FDA) approved polymer for human clinical use due to its proven 
biocompatibility and low toxicity. After removal of the solvents overnight, the molten curcumin 
and polymer was extruded through silastic tubing and cooled prior to removal from the tube. 
Based on the findings from Bansal et al. it was confirmed that an increase in implant surface area 
via changes in the diameter created an increase in drug release rate of curcumin [18]. With that 
knowledge, we wanted to test the effects of a drastic change in implant geometry on the 
degradation and drug release rate of curcumin. However, in order to achieve this geometry an 
alternative method of manufacturing was needed. Through the use of a custom compression 
mold we developed a threaded cylindrical implant to compare against a traditional cylindrical 
implant. With the drastic increase in surface area it is expected that the threaded geometry 
implants will have an increased drug release rate. Additionally, it is expected that the 
manufacturing modifications will help in scaling up manufacture of implants without 
compromising quality. 
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4.2 Materials and Methods 
4.2.1 Materials 
Poly(caprolactone) 50,000 molecular weight was purchased from (Capa 6506, Perstorp, 
Sweden). Phosphate-buffered saline powder (pH 7.4) and bovine calf serum (BCS) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Additional BCS was purchased from 
Hyclone (Logan, UT, USA). Curcumin (98% pure) was purchased from Acros Organics (Morris 
Plains, NJ, USA). No further analysis was done on any of the received materials. 
 
4.2.2 Cryomilling 
PCL was combined with curcumin at a 15% w/w ratio. Milling was done using a SPEX 
Sample Prep Freezer Mill 6770 (Metuchen, NJ, USA). PCL and curcumin were combined in a 
grinding vial and placed in the grinding chamber. The vial was precooled for 15 minutes prior to 
the start of grinding cycles. The mill was programmed for 5 cycles, a 2 minute cool time, and a 3 
minute run time at a rate of 10 cps.  
 
4.2.3 XRD Evaluation of Cryomilled PCL and Curcumin 
 In order to determine if the cryomilling process generated a homogeneous mixture of 
PCL and curcumin, XRD analysis was done over a full angle spectrum in a Rigaku Miniflex 600 
XRD analysis unit (Tokyo, Japan). The voltage and current X-ray generator applied were 40 kV 
and 15 mA respectively. A scintillation counter (SC-70) was used as the detector. Scan range 
was from 1.01 to 60 degrees at a step width of 0.02 degrees. The XRD profiles were analyzed 
using the integrated X-ray powder diffraction software, PDXL, version 2.1.3.4. 
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4.2.4 Compression Molding 
 Implants were created using two custom molds. The cylindrical rod mold created 
implants with a 2 mm diameter, while the threaded rod mold had an implant diameter of 1.5 mm 
in order to accommodate machining capabilities for the introduction of threads. Molds were 
loaded into a model 4386 model Carver hydraulic press (Wabash, IN, USA). Blank PCL 
implants were created using 50,000 molecular weight PCL at a plate temperature of 71° C. 
Curcumin loaded PCL implants were created using the cryomilled PCL and curcumin at a plate 
temperature of 71°C and compressed with 1,200 psi.  Implants were removed from the molds 
and separated from the mold stem before evaluation. Implants for both geometries were cut to a 
length of 1.30 cm. The average threaded implant mass was 22.0 ± 0.75 mg and the average 
cylindrical implant was 49.9 ± 1.04 mg. 
 
4.2.5 In Vitro Evaluation 
Implants were studied in vitro by submerging each sample (n=3 for each condition, 12 
total implants) in 10 mL of PBS solution (pH 7.4) in 20 mL amber vials. In order to better mimic 
the in vivo environment, the PBS was supplemented with BCS (10% v/v). The sample implants 
were incubated at 37° C and agitated at 150 rpm on a shaker table (I24 New Brunswick 
Incubator Shaker, Eppendorf, Germany). Samples were measured at every media change every 
48 hours.  
 
4.2.6 Spectrophotometer Characterization 
   In order to validate curcumin was present in degradation media, 1 mL of ethanol was 
added to media to solubilize residual curcumin. Media from curcumin samples was collected 
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every 2 days, n=3. Absorbance of the media was measured spectrophotometrically (DU 720, 
Beckman Coulter, CA, USA) at 430 nm as previously established [19].  A standard curve was 
used to determine the quantitative relationship between absorbance values and curcumin 
concentration present in the degradation media. Curcumin concentration range was from 100 μg-
700 μg. 
 
4.2.7 Scanning Electron Microscopy (SEM) 
 Evaluation of surface area features and the effects of degradation on physical properties 
of implants was studied using a Jeol JCM-6000 benchtop SEM (Tokyo, Japan). Implants were 
evaluated prior to in vitro degradation and after 30 days of degradation. Samples were mounted 
using carbon tape and analyzed at 15 kV.  
 
4.2.8 Statistical Analysis 
Percent mass loss values were analyzed using a two way ANOVA with significance set at 
p < 0.05. ANOVA factors were defined as geometry and curcumin loading. Percent mass loss 
values were averaged over the 30 day period for a sample size of n=3. Statistical significance for 
average daily drug release was determined using a standard two tailed t-test. Differences were 
considered significant for values where p < 0.05.  Normal distribution and equal variances were 
assumed.  
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4.3 Results 
4.3.1 XRD Evaluation of Cryomilled PCL and Curcumin 
 Figure 4.1 shows the XRD profile for the cryomilled PCL and curcumin at an 85% to 
15% ratio respectively. Comparison peaks for 100% curcumin and 100% PCL are also shown in 
Figure 4.1. This result shows that PCL and curcumin mixture has a distinct profile curve unique 
from its constituent parts. Figure 4.2 shows the XRD analysis of a solvent mixed matrix of PCL 
and curcumin in the same 85-15% ratio. There was a noticeable difference at the 10 degree point 
in the XRD characteristic peaks of the cryomilled curcumin and PCL powder in comparison to 
the solvent mixed PCL and curcumin solid dispersion. The first large characteristic peak for 
curcumin is found at the 10 degree point, and a reduced version of that peak can be found on the 
cryomilled XRD profile, but not the solvent mixed profile. 
 
4.3.2 In Vitro Results 
 In vitro release profiles for both the original cylindrical geometry and the new 
threaded geometry implants without drug loading can be found in Figure 4.3. Due to drastically 
different geometries, the starting masses for the threaded and cylindrical implants were not 
directly comparable by mass loss. Instead, percent mass loss was used to analyze changes in 
implant weight. There was no significant difference in the average percent weight loss over 30 
days of degradation between the two geometries without curcumin loading. 
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Figure 4.1: XRD profiles of 85% PCL and 15% curcumin in relation to neat PCL and curcumin 
profiles. 
 
 
 
 
Figure 4.2: XRD profiles of cryomilled 85% PCL and 15% curcumin in comparison to solvent 
mixed PCL and curcumin in the same ratio. 
29 
 
 
 
 
 
 
 
Figure 4.3: Graph of percent mass loss findings across all groups. 
 
The percent mass loss of curcumin loaded PCL cylindrical millirods (1.59 ± 0.884) was 
not significantly different from that of the blank PCL rod mass loss (0.813 ± 0.399). Similarly, a 
comparison of blank threaded PCL implants (0.837 ± 0.62) to curcumin loaded PCL threaded 
implants (3.39 ± 1.31) did not have a significantly higher average percent mass loss over the 
PCL only sample. Lastly, a comparison of average cumulative mass loss for curcumin loaded 
implants with threaded and cylindrical geometries shows that the curcumin loaded threaded 
geometry (3.39 ± 1.31)  did not have a significantly higher percent mass loss over 30 days than 
the cylindrical geometry implant with curcumin (1.59 ± 0.884). Table 4.1 shows the ANOVA 
results for the percent mass loss data.  No interactions were found to be significant at a sample 
size of three. Figure 4.4 shows sample daily percent mass loss trends for the two curcumin 
loaded implants with different geometries. 
Table 4.1 ANOVA of Cumulative Mass Loss Percentages (n=3) 
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Figure 4.4: In vitro release profiles over 30 days of degradation by percent mass loss of 15% 
curcumin loaded implants between the two different geometry types. There are no significant 
differences between treatments. 
 
4.3.3 Spectrophotometry Characterization 
The results of the spectrophotometry characterization can be found in Figure 4.5. 
Curcumin concentration was analyzed every 2 days and those values were averaged to determine 
the average daily release rate over the period of 30 days. Using the standard curve to relate 
absorbance values to μg/day release found that the threaded geometry implant had a significantly 
higher average daily release than the cylindrical geometry after accounting for mass differences.  
Threaded geometry implants released an average of 47.98 ± 0.11 μg/day, while cylindrical 
geometry implants released 33.00 ± 0.06 μg/day.  
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Figure 4.5: Average daily curcumin release values over the course of 30 days in vitro 
degradation. * denotes statistical significance. 
 
4.3.4 SEM Analysis 
 Scanning electron microscope analysis of both cylindrical and threaded millirods can be 
found in Figure 4.6. After in vitro degradation a noticeable change in surface morphology was 
observed in both geometry types. At 30 days of degradation the cylindrical implant began 
showing signs of small surface holes where there were none previously.  
 Estimated threaded implant surface area was calculated using the following equation 
[20]: 
 𝑆𝑆𝑆𝑆 = 𝜋𝜋 ∗ ��𝑏𝑏2�2 − �𝑎𝑎2�2� ∗ 𝑑𝑑𝑐𝑐 ∗ 2 ∗ 2√3 
Where a is the inner thread diameter, b is the outer thread diameter, c is the pitch length, and d is 
the length of the implant. Surface area for the threaded geometry implant was found to be 72.4 
mm2.  
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Figure 4.6: SEM images for sample millirods before and after in vitro degradation. (A) 
Cylindrical curcumin loaded millirod implant before degradation. (B) Cylindrical curcumin 
loaded millirod after 30 days of in vitro degradation. (C) Threaded curcumin loaded implant 
prior to degradation. (D) Threaded curcumin loaded implant after 30 days of degradation. 
 
4.4 Discussion 
Solvent mixing has been the primary method for creating the polymer drug matrix. 
However, this method requires additional materials in the form of solvents to dissolve the drug 
and the polymer, as well as time to remove the solvent from the mixture after the drug and 
polymer were combined. This is usually done overnight in a vacuum environment. The end 
product is a solid curcumin and polymer mass that must undergo additional processing prior to 
A B 
C D 
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being converted into its final form. Removing solvents from the polymer matrix creation would 
reduce manufacturing material costs in addition to a reduction in material processing time. 
Cryomilling can be executed in minutes rather than hours, and the end product is a powder that is 
easy to introduce into molding or extruding applications. A comparison of the XRD profiles for 
both solvent mixed and cryomilled PCL and curcumin shows similar overall trends. Peaks 
indicate diffraction intensity at different angles. These peaks are unique to crystals within a 
structure and can be used to identify differences in materials present in the sample [21]. Despite 
maintaining relatively similar peak trends, near the 10 degree mark the cryomilled mixture has a 
defined peak not present in the solvent mixed sample. This peak is a reduced intensity version of 
the curcumin characteristic peak that appears at the same degree. This retention of a main 
characteristic peak for curcumin may point to a better method of mixing without compromising 
the compound integrity. A study by Wegiel et al. utilized cryomilling as a method to create larger 
quantities of amorphous curcumin and poly(vinylpyrrolidone) mixtures [22]. From this we can 
conclude that cryomilling serves as an effective alternative method for creating a homogeneous 
powder polymer matrix in bulk manufacturing quantities. 
Additionally, the use of silastic tubing works well for small scale production of implants 
with a basic cylindrical geometry. Based on previous literature, modification of surface area is a 
way to increase drug release rate, but use of tubing limits changes to modifying diameter size 
and production volume. The use of a mold would allow for production of 8-12 implants at a time 
in addition to the potential incorporation of new surface geometries with a reduced amount of 
materials consumed during the process. Both the cylindrical and threaded geometry implants for 
this study were created through the use of a mold. This allowed for minimal post manufacturing 
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processing while allowing for the addition of complex surface geometry to the threaded implants 
that was previously not attainable. 
 In vitro degradation of the cylindrical geometry in comparison to the threaded geometry 
without drug loading was not statistically significant.  By comparing each drug loaded implant 
geometry type to its respective blank implant counterpart it was determined that increased 
surface geometry in combination with curcumin loading was not significant for percent mass loss 
degradation. Both the curcumin loaded cylindrical implant and the curcumin loaded threaded 
implant showed greater percent mass loss degradation than the blank PCL implants, however, 
due to the small sample size statistical significance was not obtained. 
 A comparison of the curcumin loaded cylindrical implant and the curcumin loaded 
threaded implant showed the threaded geometry had a 46.9% greater percent mass loss over the 
cylindrical geometry during degradation. However, an analysis of variance was run on the 
average percent mass loss values and showed no significant values at p < 0.05 indicating that a 
larger sample size is required to confirm that drug loading is a statistically significant parameter. 
Analysis of the percent mass loss from Figure 6 indicates a steady decreasing trend over the 30 
day period. No burst release kinetics were observed for either implant geometry. SEM analysis 
of the threaded implants before and after degradation show that the threaded surface geometry 
was still present and visible after 30 days of degradation. Surface area for the threaded geometry 
implant was 72.4 mm2, which is a 9.3% increase in surface area over a cylindrical implant of the 
same diameter.  
 Spectrophotometer analysis of the degradation serum showed after accounting for 
differences in implant masses that the threaded geometry implants had a higher average μg/day 
release than the cylindrical geometry. This confirms the hypothesis that an increase in surface 
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geometry would increase the drug release rate. A 100 mg cylindrical implant with a diameter of 
3.22 mm and a 20% drug load created by Gupta et al. had an average daily release of 98 µg/day 
and a cumulative release of 9.8% in 20 days [17]. Implants created for this study were not 
directly comparable to the previous findings due to differences in weight, volume, and drug load. 
However, extrapolation of mass and drug loading of the cylindrical geometry to better match the 
previous study gave an average daily release of ~70 μg/day. Differences in implant length and 
diameter would create significant differences in implant volume from the comparison implant 
and may account for discrepancies in average daily release between the two studies. 
 By using bulk manufacture of implants a cost savings could be imparted on the 
consumer. However, bulk manufacture limits the amount of customization available for the 
patient at the point of manufacture. Rather, customization for an individual patient would happen 
at the point of implantation. Customization could include the number of implants needed, the site 
of implantation, or post manufacturing modification, such as a change in implant length, to better 
meet patient dosing needs to manage neuropathy pain. The implant would be best utilized as an 
adjunct treatment to tricyclic antidepressants and antiepileptic drugs, or as a standalone pain 
relief option for patients intolerant or unaffected by current drug therapies.  
 
4.5 Conclusion  
 There is a current need for additional treatment solutions to help manage the symptoms of 
PDN without the negative side effects of the current off label prescribed drugs. Curcumin 
presents an attractive anti-inflammatory agent and glycemic regulator, but is plagued by low 
bioavailability when taken orally. By altering the shape geometry through the introduction of 
threads, an increase in percent mass loss, although not statistically significant at this sample size, 
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was observed for curcumin loaded implants. The threaded geometry implants also showed a 
higher μg/day release of curcumin in vitro than their cylindrical counterparts. By modifying 
previously used manufacturing methods, this threaded geometry feature for subcutaneous 
implants can be easily scaled up for larger manufacturing needs. 
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CHAPTER V: CONCLUSIONS & FUTURE WORK 
5.1 Conclusions 
 This thesis has summarized literature on painful diabetic neuropathy and the challenges 
that surround pain relief for those affected. Current medications in use for treatment do not fully 
relieve pain and can adversely affect quality of life for those who suffer from PDN. There is a 
need for the creation of alternative pain relief therapies specifically targeting the treatment of 
painful diabetic neuropathy.   
Effective strategies to control PDN have been to target hyperglycemia overall or block 
inflammatory and oxidative signals in cells. Curcumin is a natural compound found in the spice 
turmeric that has been shown to have anti-hyperglycemic, anti-inflammatory, and antioxidant 
effects in cells. Curcumin has been successfully used for in vivo evaluation studies focused on 
the compound’s effectiveness against diabetes. However when taken orally, curcumin has 
limited bioavailability as the digestive system metabolizes most of the active compounds. In 
order to increase the effectiveness of the compound, curcumin needs to be encapsulated. The 
focus of this research was to determine if changes to the manufacturing process for encapsulating 
curcumin in a polymer matrix would be viable options in a bulk manufacturing setting. 
Two primary manufacturing improvements to the creation of curcumin loaded millirod 
implants were established. The first is the use of cryomilling as a mixing method for the creation 
of homogeneous PCL and curcumin blends. The second was the incorporation of compression 
molding to allow for more complex surface geometry inclusions in an implant. These geometry 
inclusions were found to increase the percent mass loss of the implant in addition to increasing 
the average daily drug release over a standard cylindrical implant.  
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5.2 Review of Contribution 
 By utilizing cryomilling as a method of mixing curcumin and PCL compounds, the ease 
of manufacture of millirod implants in a scaled up manufacturing setting is greatly improved 
over solvent mixing methods. Introduction of compression molding as the main manufacturing 
process allows for previously unattainable implant surface geometries that impact implant 
degradation rate in addition to reducing the amount of materials consumed over the silastic 
tubing extrusion method. These modifications to the manufacture process are an essential step in 
moving curcumin implants from benchtop to market. 
 
5.3 Future Work 
Future studies will look at the impact of increased cryomilling time, and therefore smaller 
particle size, on average daily release of curcumin and percent mass loss implants. Evaluation of 
storage capabilities also needs to be done to determine the number of days before a PCL and 
curcumin matrix becomes crystalline. Crystallinity in curcumin is not ideal as amorphous solid 
dispersions are more soluble but less stable [54]. This study would be similar to the crystalline 
stability studies done by Wegiel, et al. [54]. The effective shelf life of the amorphous cryomilled 
powder would be crucial when considering a bulk manufacturing timeline in addition to the 
movement of finished implants through the supply chain. Another area of future work will 
include effective implant locations in vivo.
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